Significant advances have been made in the treatment of MS in recent years, and there are effective treatments for patients with MS1 


MS affects everyone differently. Having a plan that includes an assessment of any problems, incorporates your goals, identifies suitable treatments, and provides you with education and support can help you to maintain (and regain) your life activities.2

 

ICONMS treatments are envisaged as long-term therapies3

 

  • The first type of medication that is recommended is a disease modifying therapy, or a DMT1
  • DMTs can reduce the MS relapses and can help prevent or slow down any new lesions, or abnormal spots, on the brain. They do not cure MS, but they can help keep the condition stable, and some patients can have no evidence of disease activity (NEDA)2
  • Your doctor can also prescribe medicines to help with any symptoms you experience, which can be taken in addition to a DMT medication
  • You will probably see your neurologist or specialist every 3–12 months to check on your progress and how your treatment is working, and you may need to do a scan (such as an MRI) every 3-12 months at first, and then every 12 months or less after that3
  • It is important to talk to your doctor if you notice any new symptoms, or if your symptoms seem to be getting worse

Listen to Dr David Baker explain what No Evidence of Disease Activity (NEDA) means and why it can be a goal of MS treatment.

The information in this embedded video has been developed by the author(s) of the video. Novartis has not been involved in the creation of this content. The intent of providing this material is informational and not as advice. Any information provided by this source should be discussed with your healthcare professional and does not replace their advice.

Your specialist is the best person to provide advice on the available treatments. It’s OK to ask questions, and to share your concerns and fears.

 

References:

  • Rae-Grant A, et al. Neurology. 2018;90:777-788.
  • Kesselring J. Eur Neurological Rev 2017;12(1):31-36.
  • Broadley SA, et al. Med J Aust. 2015; 203(3):139-141.